DDIT4 and breast cancer: The anticancer activities of baicalein have been attributed to a variety of mechanisms that are important in breast cancer, including inhibiting 12-LOX activity [43], upregulating DDIT4 expression, inhibiting mTOR [44], and suppressing the aromatase (CYP19) activity and thus decreasing estrogen biosynthesis [45].